You are here

AFASCI, INC.

Company Information
Address
2633 MARTINEZ DR
BURLINGAME, CA 94010-5828
United States


https://www.afasci.com

Information

UEI: UGMEBNM4WSL6

# of Employees: 10


Ownership Information

HUBZone Owned: No

Socially and Economically Disadvantaged: No

Woman Owned: No



Award Charts




Award Listing

  1. Clinical Phase I trials on an IND single molecule dual inhibitor of Cav3 channels and soluble epoxide hydrolase for treatment of neuropathic pain

    Amount: $1,499,931.00

    7. PROJECT SUMMARY We propose conducting clinical Phase I trials on an active IND (157314), AFA-281, a non-opioid, single small molecule that inhibits both T-type Cav3 calcium channels and soluble epo ...

    SBIRPhase II2023Department of Health and Human Services National Institutes of Health
  2. Development of a Novel Medication for Alcohol Use Disorder with an Active IND Dual Inhibitor of T-Type Calcium Channel and Soluble Epoxide Hydrolase

    Amount: $483,851.00

    7. SUMMARY Alcohol use disorder (AUD) is the most prevalent substance use disorder worldwide and often co-occurs with chronic pain, anxiety, depression, and opioid dependence. Unfortunately, currently ...

    SBIRPhase I2023Department of Health and Human Services National Institutes of Health
  3. Developing a novel treatment of cocaine use disorder using an IND dual inhibitor of Cav3 channel and soluble epoxide hydrolase

    Amount: $319,547.00

    7. PROJECT SUMMARY Our SBIR Phase I proposal focuses on preclinical proof of concept studies on our IND AFA-281 for treatment cocaine use disorder (CUD). AFA-281 is a new chemical entity discovered by ...

    SBIRPhase I2023Department of Health and Human Services National Institutes of Health
  4. Development of a Next Generation Visual Performance Assessment System for Rodents

    Amount: $1,480,057.00

    7. PROJECT SUMMARY Title: Development of a Next Generation Visual Performance Assessment System for Rodents Visual behavior abnormalities not only link directly to the retinal pathology and visual pat ...

    SBIRPhase II2019Department of Health and Human Services National Institutes of Health
  5. IND-enabling studies on novel Cav3 T-channel modulators for treatment of neuropathic pain

    Amount: $2,983,561.00

    7. PROJECT SUMMARY Neuropathic pain remains a poorly managed medical condition affecting more than 1.5 billion people worldwide. Over 20 million people suffered from diabetic neuropathy and neuropathi ...

    SBIRPhase II2018Department of Health and Human Services National Institutes of Health
  6. Discovering GIRK Channel Direct Activator as a Novel Chronic Insomnia Therapeutic

    Amount: $399,429.00

    PROJECT SUMMARY Millions of Americans suffer from sleep disturbances among which insomnia is the most commonInsomnia is often poorly treated with current pharmacotherapies and we propose to develop a ...

    SBIRPhase I2018Department of Health and Human Services National Institutes of Health
  7. Development of patented tricyclic pyrones molecules for the treatment of Alzheimer's Disease

    Amount: $2,174,709.00

    Project Summary Abstract Alzheimer s diseaseADafflicts approximatelymillion people worldwide and is the most common cause of dementia in the elderlyThere is an unmet medical need for the development o ...

    SBIRPhase II2017Department of Health and Human Services National Institutes of Health
  8. Developing a novel CGRP antagonist for treatment of dental neuroinflammatory pain

    Amount: $221,872.00

    DESCRIPTION provided by applicant Management of pain and inflammation is the most critical aspect of dental practice Inadequate pain control affects patients in many ways beyond the treatment and ...

    SBIRPhase I2016Department of Health and Human Services National Institutes of Health
  9. Sample-free onsite detection of cocaine using microneedles via laser-treated skin

    Amount: $223,633.00

    DESCRIPTION provided by applicant The abuse of illicit drugs such as cocaine marijuana and heroin remains a critical public health concern throughout the country and is associated with staggering ...

    STTRPhase I2016Department of Health and Human Services National Institutes of Health
  10. A Visual Assessment System for Retinal Function/Drug Discovery

    Amount: $233,235.00

    DESCRIPTION provided by applicant Preclinical evaluation of treatment strategies for retinal neurodegenerative diseases is highly dependent on mouse models Classical methods to assess the visual f ...

    STTRPhase I2015Department of Health and Human Services National Institutes of Health
US Flag An Official Website of the United States Government